Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$1.09 - $1.89 $403,191 - $699,111
-369,900 Reduced 27.0%
1,000,000 $1.09 Million
Q3 2021

Nov 15, 2021

BUY
$1.44 - $2.73 $1.97 Million - $3.74 Million
1,369,900 New
1,369,900 $2.49 Million

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $443M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.